Rasagiline Mesylate
5 NDCs across 3 manufacturers|3 Generic,2 Brand
Rasagiline Mesylate is used to treat parkinson disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 16, 2006, and the first generic was approved Jul 1, 2013. FDA's Orange Book lists 22 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $30 million on Rasagiline Mesylate across 148,000 claims for 32,000 beneficiaries.
Rasagiline Mesylate is available as 5 NDCs from 3 manufacturers (3 generic, 2 brand), with NADAC prices from $0.52 to $44.08 per EA — the most expensive product costs about 85× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
5
3G / 2B
Manufacturers
3
competing in market
Price Spread
$0.52 – $44.08
per EA
7d Activity
avg +6.3% WoW · of 5 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Teva Neuroscience, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Monoamine Oxidase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
3 manufacturers producing RASAGILINE MESYLATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
AZILECT 1 MG TABLET | $44.0804 per EA | — |
AZILECT 0.5 MG TABLET | $44.0463 per EA | — |
RASAGILINE MESYLATE 1 MG TAB | $0.9255 per EA | -10.31% |
RASAGILINE MESYLATE 0.5 MG TAB | $0.5209 per EA | +14.59% |
RASAGILINE MESYLATE 0.5 MG TAB | $0.5209 per EA | +14.59% |
Frequently Asked Questions
What is Rasagiline Mesylate used to treat?
Rasagiline Mesylate is used to treat parkinson disease, per the National Library of Medicine's MED-RT classification.
When did Rasagiline Mesylate become available as a generic?
FDA approved the first generic Rasagiline Mesylate (ANDA) on Jul 1, 2013. The Orange Book currently lists 22 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rasagiline Mesylate?
In 2024, Medicare Part D spent $30 million on Rasagiline Mesylate across 148,000 claims for 32,000 beneficiaries.
How many Rasagiline Mesylate products are on the market?
The Rasagiline Mesylate drug market contains 5 NDCs from 3 manufacturers — 3 generic and 2 brand products.
What is the price range for Rasagiline Mesylate?
NADAC reference prices for Rasagiline Mesylate range from $0.5209 to $44.0804 per EA — the most expensive product costs about 85× the cheapest.
Is generic Rasagiline Mesylate cheaper than brand?
The average generic NADAC for Rasagiline Mesylate is $0.6557 per EA, versus $44.0634 for brand-labeled products — brand versions average about 67× the generic price.
Which manufacturers make Rasagiline Mesylate?
3 manufacturers list Rasagiline Mesylate in NADAC. Ranked by number of NDCs, the largest are Teva Neuroscience, Inc. (2), Avet Pharmaceuticals Inc. (2), Rising Pharma Holdings Inc. (1).
How has the price of Rasagiline Mesylate changed recently?
Over the past 7 days, 2 Rasagiline Mesylate NDCs rose and 1 fell, with a market-wide average change of +6.3%.